



Preclinical development of PKMYT1 and ATR inhibitor combinations

David Gallo¹, Marc L. Hyer², Rosie Kryczka¹, Adam Petrone², Elia Aguado-Fraile², Jimmy Fourtounis¹, Vivek Bhaskaran¹, Rino Stocco¹, Ariya Shiwram¹, Stephen J. Morris¹, Anne Roulston¹, C. Gary Marshall², Michael Zinda², Michal Zimmermann¹

¹Repare Therapeutics, St-Laurent, QC, Canada, ²Repare Therapeutics, Cambridge, MA, USA

*Gallo, Young, Fourtounis et al., 2022, Nature 604(7907):749-756









Poster # B057



Camonsertib enhances CDK1 activation and premature mitosis in lunresertib-treated cells

• Addition of camonsertib to lunresertib triggers faster and stronger CDK1 activation and premature mitotic entry from S-phase than lunresertib single-agent